Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: INOMAX

« Back to Dashboard
Inomax is a drug marketed by INO and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in INOMAX is nitric oxide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nitric oxide profile page.

Summary for Tradename: INOMAX

Suppliers / Packagers: see list4

Pharmacology for Tradename: INOMAX

Drug ClassVasodilator
Physiological EffectVasodilation

Clinical Trials for: INOMAX

Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children
Status: Completed Condition: Acute Chest Syndrome; Sickle Cell Disease

Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing
Status: Completed Condition: Idiopathic Pulmonary Arterial Hypertension; Congenital Heart Disease With Pulmonary Hypertension; Cardiomyopathy

Effect of Nitric Oxide (NO) on Ischemic/Reperfusion Injury During Extended Donor Criteria (EDC) Liver Transplantation
Status: Recruiting Condition: Liver Transplantation; Ischemia/Reperfusion Injury; Oxidative Injury

Nitric Oxide Administration for Acute Respiratory Distress Syndrome
Status: Completed Condition: Acute Respiratory Distress Syndrome

The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation
Status: Completed Condition: Congestive Heart Failure

Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia
Status: Completed Condition: Pulmonary Disease

Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure
Status: Withdrawn Condition: Hypoxic Respiratory Failure With Pulmonary Hypertension

Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
Status: Recruiting Condition: Heart Failure

Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
Status: Completed Condition: Anemia, Sickle Cell

Phase II Evaluation of Exhaled Nitric Oxide (NO)
Status: Completed Condition: Lung Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
nitric oxide
GAS;INHALATION020845-002Dec 23, 1999DISCNNo8,573,210*PED<disabled>Y<disabled>
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYes8,795,741*PED<disabled>Y<disabled>
nitric oxide
GAS;INHALATION020845-003Dec 23, 1999RXYes8,282,966*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: INOMAX

Drugname Dosage Strength RLD Submissiondate
nitric oxidefor Inhalation100 ppm and 800 ppmINOmax5/20/2014
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn